AstraZeneca touts Imfinzi immunotherapy combos for lung cancer in push to drive PD-L1 drug uptake
Facing the big dogs in the PD-(L)1 space, AstraZeneca has taken its own contender Imfinzi into blockbuster territory in its four years on the market …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
